Trial Profile
A Phase 3 Clinical Study Protocol: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Study of APF530 500 mg SC, Fosaprepitant 150 mg IV, and Dexamethasone vs. Ondansetron 0.15 mg/kg IV, Fosaprepitant 150 mg IV, and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Dec 2016
Price :
$35
*
At a glance
- Drugs Granisetron (Primary) ; Dexamethasone; Fosaprepitant; Ondansetron
- Indications Chemotherapy-induced nausea and vomiting
- Focus Registrational; Therapeutic Use
- Acronyms MAGIC
- Sponsors Heron Therapeutics
- 11 Aug 2016 According to a Heron Therapeutics media release, based on this and other study (CTP 700011680) the US FDA has approved granisetron extended-release injection for the prevention of chemotherapy-induced nausea and vomiting.
- 07 Jun 2016 Results (subgroup analysis, n = 902) assessing efficacy and safety by age and gender presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology